دورية أكاديمية
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
| العنوان: | Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia |
|---|---|
| المؤلفون: | Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani Morales, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Luis, Sanz, Miguel Ángel, Solano Vercet, Carlos, de la Rubia Comos, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime |
| سنة النشر: | 2022 |
| المجموعة: | Universitat de València: Roderic - Repositorio de contenido libre |
| مصطلحات موضوعية: | Patologia |
| الوصف: | Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | Bone Marrow Transplantation, 2022; Lazzari, Lorenzo Balaguer-Roselló, Aitana Montoro, Juan Greco, Raffaella Hernani Morales, Rafael Lupo-Stanghellini, Maria Teresa Villalba, Marta Giglio, Fabio Facal, Ana Lorentino, Francesca Guerreiro, Manuel Bruno, Alessandro Pérez, Ariadna Xue, Elisabetta Clerici, Daniela Piemontese, Simona Piñana, Jose Luis Sanz, Miguel Ángel Solano Vercet, Carlos de la Rubia Comos, Javier Ciceri, Fabio Peccatori, Jacopo Sanz, Jaime 2022 Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia Bone Marrow Transplantation; https://hdl.handle.net/10550/83733Test; 154548 |
| DOI: | 10.1038/s41409-022-01725-3 |
| الإتاحة: | https://doi.org/10.1038/s41409-022-01725-3Test https://hdl.handle.net/10550/83733Test |
| حقوق: | open access |
| رقم الانضمام: | edsbas.467F9FB3 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41409-022-01725-3 |
|---|